Literature DB >> 15316202

Interstitial lung disease induced by drugs and radiation.

Philippe Camus1, Annlyse Fanton, Philippe Bonniaud, Clio Camus, Pascal Foucher.   

Abstract

An ever-increasing number of drugs can reproduce variegated patterns of naturally occurring interstitial lung disease (ILD), including most forms of interstitial pneumonias, alveolar involvement and, rarely, vasculitis. Drugs in one therapeutic class may collectively produce the same pattern of involvement. A few drugs can produce more than one pattern of ILD. The diagnosis of drug-induced ILD (DI-ILD) essentially rests on the temporal association between exposure to the drug and the development of pulmonary infiltrates. The histopathological features of DI-ILD are generally consistent, rather than suggestive or specific to the drug etiology. Thus, the diagnosis of DI-ILD is mainly made by the meticulous exclusion of all other possible causes. Drug dechallenge produces measurable improvement in symptoms and imaging in the majority of patients, whereas corticosteroid therapy is indicated if symptoms are present or drug dechallenge is without an effect. Rechallenge is justified in a minority of patients, and is discouraged for diagnostic purposes only. Pneumotox (www.pneumotox.com) provides updated information on drug-induced respiratory disease. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316202     DOI: 10.1159/000079633

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  91 in total

1.  Everolimus-related organizing pneumonia: a report establishing causality.

Authors:  Justine Frija; Dominique Joly; Bertrand Knebelmann; Daniel Dusser; Pierre-Régis Burgel
Journal:  Invest New Drugs       Date:  2010-12-29       Impact factor: 3.850

2.  AJRCCM: 100-Year Anniversary. Progress in Interstitial Lung Disease.

Authors:  Robert J Kaner; Kevin K Brown; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2017-05-01       Impact factor: 21.405

3.  Feasibility and effectiveness of inhaled carboplatin in NSCLC patients.

Authors:  Paul Zarogoulidis; Ellada Eleftheriadou; Iordanis Sapardanis; Vasiliki Zarogoulidou; Helliel Lithoxopoulou; Theodoros Kontakiotis; Nikolaos Karamanos; George Zachariadis; Maria Mabroudi; Athanasios Zisimopoulos; Kostantinos Zarogoulidis
Journal:  Invest New Drugs       Date:  2011-07-08       Impact factor: 3.850

Review 4.  Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings.

Authors:  Fumikazu Sakai; Takeshi Johkoh; Masahiko Kusumoto; Hiroaki Arakawa; Masahiro Takahashi
Journal:  Int J Clin Oncol       Date:  2012-11-10       Impact factor: 3.402

5.  A case of maoto-induced interstitial pneumonia.

Authors:  Masaru Ando; Taiki Masuda; Mari Yamasue; Shin-Ichi Nureki; Eishi Miyazaki; Jun-Ichi Kadota
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

6.  Development of cocaine-induced interstitial lung damage in two CYP2C and VKORC1 variant allele carriers.

Authors:  Petal A H M Wijnen; Otto Bekers; Marjolein Drent
Journal:  Mol Diagn Ther       Date:  2011-06-01       Impact factor: 4.074

Review 7.  Interstitial lung diseases in children.

Authors:  Annick Clement; Nadia Nathan; Ralph Epaud; Brigitte Fauroux; Harriet Corvol
Journal:  Orphanet J Rare Dis       Date:  2010-08-20       Impact factor: 4.123

8.  Ionizing radiation induces myofibroblast differentiation via lactate dehydrogenase.

Authors:  J L Judge; K M Owens; S J Pollock; C F Woeller; T H Thatcher; J P Williams; R P Phipps; P J Sime; R M Kottmann
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-07       Impact factor: 5.464

9.  Six minute walking test and carbon monoxide diffusing capacity for non-small cell lung cancer: easy performed tests in every day practice.

Authors:  Paul Zarogoulidis; Theodora Kerenidi; Haidong Huang; Theodoros Kontakiotis; Ourania Tremma; Konstantinos Porpodis; Anastasios Kalianos; Ageliki Rapti; Christoforos Foroulis; Athanasios Zissimopoulos; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

10.  Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model.

Authors:  Takayoshi Fujibayashi; Naozumi Hashimoto; Mayumi Jijiwa; Yoshinori Hasegawa; Toshihisa Kojima; Naoki Ishiguro
Journal:  BMC Pulm Med       Date:  2009-09-16       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.